MorphoSys AG, a late-stage, biopharmaceutical company, announced that country subsidiaries of its licensee Janssen reported that Tremfya (guselkumab) has been approved for the treatment of adults living with moderate to severe plaque psoriasis in Brazil and Australia.

As reported by Janssen-Cilag Farmacêutica Ltda. (Janssen), the Brazilian National Health Surveillance Agency (ANVISA) has approved Tremfya for the treatment of adults living with moderate to severe plaque psoriasis. Janssen-Cilag Pty Limited (Janssen) announced that Tremfya has been approved by the Therapeutic Goods Administration (TGA) and registered on the Australian Register of Therapeutic Goods (ARTG) for the treatment of adults living with moderate to severe plaque psoriasis in Australia.

Tremfya is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys's proprietary HuCAL antibody library technology.

MorphoSys is eligible to receive royalties on net sales of Tremfya.

Dr. Markus Enzelberger, chief scientifc officer of MorphoSys AG, said: "We are very pleased about the Tremfya approvals in Brazil and Australia. Thus Tremfya has now been approved in a number of territories worldwide, including the US, Canada, the European Union, Brazil, and Australia. We expect Tremfya will continue to provide an important treatment option for patients living with moderate-to-severe plaque psoriasis."

In addition to psoriasis, Tremfya is in phase 3 development in psoriatic arthritis. Janssen has announced plans to investigate guselkumab in Crohn's disease.

MorphoSys is a late-stage, biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases.